|
|
||||||||
746.20 |
1 Physiology & Biophysics, Georgetown University, Washington, DC
2 Neurobiology, Garvan Institute of Medical Research, Sydney, Australia
ABSTRACT
Previously, we showed that sympathetically-derived NPY promotes ischemic revascularization after femoral artery occlusion (FAO) in rodents by activating Y2 receptors (Rs) and dipeptidyl peptidase IV (DPPIV), which forms a Y2/Y5-preferring agonist. The role of other NPY sources (platelets), Rs and temporal relationship to ischemic revascularization was unknown and is studied here. A critical role for NPY but not Y5R was shown in NPY–/– and Y5–/– mice whose post-FAO limb revascularization was markedly impaired and unchanged, respectively. Within 5 days, FAO in rats (expressing platelet NPY) elevated plasma NPY levels (neuronal) and Y1, Y2, DPPIV and NPY mRNA (vs. non-ischemic contralateral limb) in adductor (arteriogenesis zone) and gastrocnemius (angiogenesis zone) muscles; while density of CD31+-capillaries fell. Vascular density, CD31+- and smooth muscle
-actin+-vessels, was restored by 14 days, when platelet levels doubled, and accelerated to 5 days by NPY slow-release pellet (below FAO, 1 µg/14 days). Platelet NPY and bone marrow NPY mRNA were increased after FAO in platelet NPY-expressing Sv129 WT mice, which were then used in a platelet depletion/transfer experiment [found (KA) to restore NPY atherosclerotic effects in resistant NPY–/–] with NPY–/–mice. Thus, early activation of neuronal and later activation of megakaryocyte/platelet-derived NPY is essential for ischemic revascularization. NIH grants HL067357 and HL055310 to Z.Z.
| ||||||||||||||||||||||||||||||||||||||||||||